SI
UTHR icon

Sofinnova Investments’s United Therapeutics UTHR Stock Holding History

Sofinnova Investments’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-80,300
Closed -$47.6M – 84
2026
Q1 		$47.6M Buy
+80,300
New +$40M 1.81% 17
2025
Q4 		– Sell
-97,100
Closed -$40.7M – 72
2025
Q3 		$40.7M Buy
+97,100
New +$32.7M 2.23% 16
2021
Q4 		– Sell
-94,500
Closed -$17.4M – 79
2021
Q3 		$17.4M Buy
+94,500
New +$18.6M 1.03% 22

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Sofinnova Investments's UTHR Position: Q2 2026 in Review

Sofinnova Investments reduced its United Therapeutics (UTHR) stake by 52% in Q2 2026, selling an estimated $47.1M and leaving 76,489 shares worth $41.4M. The position accounts for 2.14% of the portfolio, ranked #14.

Sofinnova Investments first reported a position in UTHR in Q3 2019 and has held it in 19 quarters since. The position peaked at $94.9M in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Sofinnova Investments held 76,489 shares of United Therapeutics worth $41.4M as of Q2 2026.
  • Sofinnova Investments sold 83,581 United Therapeutics shares in Q2 2026, an estimated $47.1M.
  • United Therapeutics made up 2.14% of Sofinnova Investments's portfolio in Q2 2026, its #14 holding.
  • Sofinnova Investments first reported a position in United Therapeutics in Q3 2019 and has held it in 19 quarters since.
  • Sofinnova Investments's United Therapeutics position peaked at $94.9M in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Sofinnova Investments's 13F filing for Q2 2026, filed 14 Aug 2026.